基于PI-RADS评分选择最佳前列腺穿刺方法:Trio研究二次分析
该研究为Trio研究的二次分析,纳入MRI可见前列腺病灶的男性,均接受联合靶向穿刺(TBx)加系统穿刺(SBx)。按PI-RADS评分分层,PI-RADS 5病灶几乎全部csPC由TBx检出,加SBx仅多检出2.5%的GG≥2癌;PI-RADS 3-4病灶加SBx检出csPC更多(8% vs 7.5%);PI-RADS 2病灶TBx对csPC检出贡献小(2% vs 7.8%)。结论:PI-RADS 5可仅行TBx,PI-RADS 3-4应联合穿刺,可减少过度穿刺且漏诊csPC风险低(1%)。
要点
- PI-RADS 5病灶仅行靶向穿刺可减少穿刺针数,漏诊csPC风险约1%。
- PI-RADS 3-4病灶联合穿刺较单独靶向穿刺检出更多csPC(8% vs 7.5%)。
- PI-RADS 2病灶靶向穿刺对csPC检出贡献小(2% vs 7.8%)。
核心结论
- 联合穿刺对MRI可见病灶男性的csPC检出增益主要限于PI-RADS 3-4病灶。
- PI-RADS 5仅行TBx、PI-RADS 3-4行联合穿刺的策略可避免PI-RADS 5的过度穿刺且漏诊csPC风险低(1%)。
研究设计与样本
- Trio研究二次分析,纳入MRI可见前列腺病灶并接受联合TBx加SBx的男性。
- 按PI-RADS评分分层比较TBx与SBx对GG≥2和GG≥3前列腺癌的检出率。
- 试验注册号ClinicalTrials.gov NCT00102544。
主要发现
- PI-RADS 5病例中加SBx仅多检出2.5%的GG≥2癌。
- PI-RADS 3-4病例中加SBx检出csPC多于单独TBx(8% vs 7.5%)。
- PI-RADS 2病例中TBx对csPC检出贡献小(2%)而SBx为7.8%。
关键数值与推荐
- PI-RADS 5:推荐仅行靶向穿刺(TBx)。
- PI-RADS 3-4:推荐联合靶向穿刺加系统穿刺(TBx+SBx)。
- 采用上述策略漏诊csPC风险为1%。
临床怎么用
- 根据术前MRI的PI-RADS评分个体化选择穿刺方式,PI-RADS 5可免去系统穿刺以减少针数。
- PI-RADS 3-4应行联合穿刺以降低csPC漏诊。
- PI-RADS 2病灶靶向穿刺价值有限,需结合系统穿刺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While magnetic resonance imaging (MRI)-targeted biopsy (TBx) results in better prostate cancer (PCa) detection relative to systematic biopsy (SBx), the combination of both methods increases clinically significant PCa detection relative to either Bx method alone. However, combined Bx subjects patients to higher number of Bx cores and greater detection of clinically insignificant PCa. OBJECTIVE: To determine if prebiopsy prostate MRI can identify men who could forgo combined Bx without a substantial risk of missing clinically significant PCa (csPC). DESIGN, SETTING, AND PARTICIPANTS: Men with MRI-visible prostate lesions underwent combined TBx plus SBx. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcomes were detection rates for grade group (GG) ≥2 and GG ≥3 PCa by TBx and SBx, stratified by Prostate Imaging-Reporting and Data System (PI-RADS) score. RESULTS AND LIMITATIONS: Among PI-RADS 5 cases, nearly all csPCs were detected by TBx, as adding SBx resulted in detection of only 2.5% more GG ≥2 cancers. Among PI-RADS 3-4 cases, however, SBx addition resulted in detection of substantially more csPCs than TBx alone (8% vs 7.5%). Conversely, TBx added little to detection of csPC among men with PI-RADS 2 lesions (2%) relative to SBx (7.8%). CONCLUSIONS: While combined Bx increases the detection of csPC among men with MRI-visible prostate lesions, this benefit was largely restricted to PI-RADS 3-4 lesions. Using a strategy of TBx only for PI-RADS 5 and combined Bx only for PI-RADS 3-4 would avoid excess biopsies for men with PI-RADS 5 lesions while resulting in a low risk of missing csPC (1%). PATIENT SUMMARY: Our study investigated an optimized strategy to diagnose aggressive prostate cancer in men with an abnormal prostate MRI (magnetic resonance imaging) scan while minimizing the risk of excess biopsies. We used a scoring system for MRI scan images called PI-RADS. The results show that MRI-targeted biopsies alone could be used for men with a PI-RADS score of 5, while men with a PI-RADS score of 3 or 4 would benefit from a combination of MRI-targeted biopsy and systematic biopsy. This trial is registered at ClinicalTrials.gov as NCT00102544.
引用
- Ahdoot M, Lebastchi AH, Long L, et al. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. Eur Urol Oncol. 2021. PMID: 33846112. doi:10.1016/j.euo.2021.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。